Results 171 to 180 of about 1,148,268 (263)

Inducing TRIB2-targeted protein degradation to reverse chemoresistance in acute myeloid leukaemia. [PDF]

Biochem J
Rigby E, Fasanella Masci F, Narayanan A, Kania E, Harris JA, Williams J, Zhang B, Liu L, Richmond L, Zhou F, Ding K, Carmody RJ, Eyers PA, Keeshan K.   +13 more
europepmc   +1 more source

Longitudinal Assessment of Biomarkers in ALS: Discriminative Biomarkers for Disease Progression and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers, Yueh‐Yun Lin, Jason R. Thonhoff, Aaron D. Thome, Alireza Faridar, Weihua Zhao, Shixiang Wen, Stanley H. Appel   +7 more
wiley   +1 more source

Targeted protein degradation: species, diseases and efficient utilization. [PDF]

J Transl Med
Yue T, He J, Hou J.
europepmc   +1 more source

Recurrent Hypothermia and Autonomic Dysfunction Secondary to Shapiro Syndrome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT A 44‐year‐old man presented with recurrent hypothermia, diaphoresis and hypertension. Extensive investigation for infectious, inflammatory, metabolic and endocrine aetiologies was negative. MR scan of the brain demonstrated no lesions but revealed callosal dysgenesis, consistent with Shapiro syndrome.
Naveen Kumar, Jeremy Johnson, Susanne Watkins, Eoin Mulroy   +3 more
wiley   +1 more source

Coiled-coil scaffolds for Targeted Protein Degradation

Korona B, Mylemans B, Acevedo-Jake AM, Huang DT, Edwards TA, Wilson AJ, Woolfson DN, Itzhaki LS.   +7 more
europepmc   +1 more source

Unlocking the "undruggable": current landscape and emerging frontiers in lysosomal receptor-mediated protein degradation. [PDF]

Drug Deliv
Ma YM, Xia HF, Xiao YL, Yu ZL.
europepmc   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw, Karishma Randhave, Ekta Anand, Ziang (Debbie) Song, Wangzhen Shen, Jing‐Qiong Kang   +5 more
wiley   +1 more source

PtCP1 Is an Extraplastidial Cysteine Protease Involved in Leaf Protein Degradation of <i>Populus tomentosa Carr</i>. [PDF]

Plants (Basel)
Fan Y, Han J, Liu X, Liu H, Zhang M, Cui X, Li H, Lu H.   +7 more
europepmc   +1 more source

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers, Yaqiao Wei, Dinesh K. Deelchand, Adam Berrington, Young Woo Park, Guita Banan, Michal Povazan, Jens T. Rosenberg, André J. W. van der Kouwe, Tetsuo Ashizawa, Khalaf O. Bushara, Chiadi U. Onyike, Sub H. Subramony, Jeremy D. Schmahmann, Brian J. Soher, Peter B. Barker, Thomas H. Mareci, Eva‐Maria Ratai, Lynn E. Eberly, Gülin Öz   +19 more
wiley   +1 more source

A cytokine receptor-targeting chimera toolbox for expanding extracellular targeted protein degradation. [PDF]

Proc Natl Acad Sci U S A
Kumru K, Yao Z, Holmes BB, Zhao F, Zhang Y, Ferrara E, Peters-Clarke TM, Leung KK, Wells JA.   +8 more
europepmc   +1 more source